Longcheng Wang

USPTO Granted Patents = 14 (Patent Applications = 10)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 5.2

ph-index = 5

Forward Citations = 116(Granted Patents)

Company Filing History:

Years Active: 2010-2018

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9862722 - Inhibitors of Bruton's tyrosine kinase (2018-01-09),

2. 9708326 - Inhibitors of bruton's tyrosine kinase (2017-07-18),

3. 9624224 - Inhibitors of Bruton's tyrosine kinase (2017-04-18),

4. 9580416 - Inhibitors of Bruton's tyrosine kinase (2017-02-28),

5. 9540385 - Pyrrolopyrimidine compounds as kinase inhibitors (2017-01-10),

6. 9533991 - Inhibitors of Bruton's tyrosine kinase (2017-01-03),

7. 9469642 - Purinone compounds as kinase inhibitors (2016-10-18),

8. 9138436 - Inhibitors of Bruton's tyrosine kinase (2015-09-22),

9. 9096604 - Pyrrolopyrimidine compounds as kinase inhibitors (2015-08-04),

10. 8710038 - Pyrazole kinase modulators and methods of use (2014-04-29),

11. 8247408 - Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer (2012-08-21),

12. 8044062 - Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha (2011-10-25),

13. 8012956 - Tropane compounds (2011-09-06),

14. 7704995 - Protein kinase modulators and methods of use (2010-04-27),

Title: Innovations and Impact of Inventor Longcheng Wang

Introduction

Longcheng Wang, based in Palo Alto, California, is a distinguished inventor renowned for his contributions to the field of pharmaceutical science. With an impressive portfolio of 14 patents, his work primarily focuses on developing inhibitors for Bruton's tyrosine kinase, which plays a crucial role in treating various diseases.

Latest Patents

Among his latest innovations are several patents concentrated on kinase inhibitor compounds. His first noteworthy patent describes methods for synthesizing these inhibitors and their application in treating diseases. Another key patent discloses compounds capable of forming covalent bonds with Bruton's tyrosine kinase (Btk), indicating a significant advancement in creating irreversible inhibitors for therapeutic use. Furthermore, he has developed reversible inhibitors of Btk and has outlined pharmaceutical compositions that include these innovative compounds. The methods delineated in his patents showcase the potential for treating autoimmune diseases, heteroimmune disorders, cancer—including lymphoma—and inflammatory conditions.

Career Highlights

Longcheng Wang's career is marked by his significant roles at prominent companies in the biotechnology sector. He has worked with renowned organizations such as Pharmacyclics, Inc. and Exelixis, Inc., where he leveraged his expertise to advance research and develop groundbreaking therapies.

Collaborations

Throughout his career, Longcheng has collaborated with esteemed professionals in the field. Notable coworkers include Wei Yu Chen and David J Loury, with whom he has shared insights and engaged in innovative projects.

Conclusion

Longcheng Wang stands as a pivotal figure in the realm of innovations focused on Bruton's tyrosine kinase. His extensive research and numerous patents underline his commitment to addressing critical health challenges through targeted therapies. As he continues to push the boundaries of scientific inquiry, his contributions promise to impact the healthcare industry significantly.

This text is generated by artificial intelligence and may not be accurate.